Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
ZHEJIANG A&F UNIVERSITY has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 distinct examiners and 2 distinct art units, indicating separate examination tracks.
BERKE-SCHLESSEL, DAVID W is the busiest examiner, with 1 pending matter. Counsel should evaluate each action in its own art-unit context while maintaining consistent positions where the underlying biotechnology issues overlap.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| §101 + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERKE-SCHLESSEL, DAVID W | 1 | 66.8% | +31.5% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18968265 | LAGENIDIUM JURACYAE WITH BURSAPHELENCHUS XYLOPHILUS (B. XYLOPHILUS)-KILLING ACTIVITY AND USE THEREOF IN CONTROL OF B. XYLOPHILUS | BERKE-SCHLESSEL, DAVID W | — |
| 18582848 | PROTEIN-DERIVED PEPTIDE FOR IMPROVING IMMUNITY AGAINST 2019 NOVEL CORONAVIRUS (2019-nCoV) AND USE THEREOF | VARADARAJ, ARCHANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18968265 | LAGENIDIUM JURACYAE WITH BURSAPHELENCHUS XYLOPHILUS (B. XYLOPHILUS)-KILLING ACTIVITY AND USE THEREOF IN CONTROL OF B. XYLOPHILUS | BERKE-SCHLESSEL, DAVID W | — |
| 18582848 | PROTEIN-DERIVED PEPTIDE FOR IMPROVING IMMUNITY AGAINST 2019 NOVEL CORONAVIRUS (2019-nCoV) AND USE THEREOF | VARADARAJ, ARCHANA | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18968265 | LAGENIDIUM JURACYAE WITH BURSAPHELENCHUS XYLOPHILUS (B. XYLOPHILUS)-KILLING ACTIVITY AND USE THEREOF IN CONTROL OF B. XYLOPHILUS | BERKE-SCHLESSEL, DAVID W | 1651 | §101 | Non-Final OA | — | Pending | Dec 04, 2024 |
| 18582848 | PROTEIN-DERIVED PEPTIDE FOR IMPROVING IMMUNITY AGAINST 2019 NOVEL CORONAVIRUS (2019-nCoV) AND USE THEREOF | VARADARAJ, ARCHANA | 1658 | §101§102§112 | Non-Final OA | — | Pending | Feb 21, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZHEJIANG A&F UNIVERSITY has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
David W Berke-Schlessel has the most, with 1 of ZHEJIANG A&F UNIVERSITY's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
